The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors

Internal Medicine

Volumn 57, Issue 15, 2018, Pages 2105-2114

  Ito, Marie ^a   Tanaka, Tetsuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Diabetic kidney disease; Final common pathway; Sodium glucose cotransporter 2 (SGLT2) inhibitors; Tubuloglomerular feedback (TGF)

Indexed keywords

ALBUMIN; CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE BODY; OXYGEN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER;

ANEMIA; BLOOD PRESSURE REGULATION; BODY WEIGHT; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FRACTURE; GLOMERULUS FILTRATION; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC PRECONDITIONING; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; LEG AMPUTATION; NEPHRITIS; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG EFFECT; FIBROSIS; INFLAMMATION; KIDNEY; METABOLISM;

BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FIBROSIS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; KIDNEY; KIDNEY TUBULES, PROXIMAL; SODIUM-GLUCOSE TRANSPORT PROTEINS; URIC ACID;

EID: 85051113901     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.9842-17     Document Type: Review

References (29)

1. ŠkrtićM, Cherney DZI. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24: 96-103, 2015.
2. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. AJP Regul Integr Comp Physiol 300: R1009-R1022, 2011.
3. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962-971, 2014.
4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373: 2117-2128, 2015.
5. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323-334, 2016.
6. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.
7. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008: 305403, 2008.
8. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306: F194-F204, 2014.
9. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8: e54442, 2013.
10. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
11. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39: 1115-1122, 2016.
12. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “Thrifty Substrate” hypothesis. Diabetes Care 39: 1108-1114, 2016.
13. Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24: 200-202, 2016.
14. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 129: 542-544, 2014.
15. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587-597, 2014.
16. Körner A, Eklöf AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43: 629-633, 1994.
17. 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309: F227-F234, 2015.
18. Layton AT, Vallon V, Edwards A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol 310: F1269-F1283, 2016.
19. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853-862, 2013.
20. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8: 844-847, 2016.
21. Chang Y-K, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 11: e0158810, 2016.
22. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343: d4169, 2011.
23. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509-514, 2014.
24. Groop P-H, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1: 100-110, 2005.
25. Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens 18: 428-432, 2009.
26. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 5: 53-61, 2014.
27. Kapoor S, Rodriguez D, Riwanto M, et al. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS One 10: e0125603, 2015.
28. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101: 157-166, 2016.
29. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101: 44-51, 2016.